Acne Vaccine Study

About the Study

Acne is one of the most common skin conditions worldwide. This study is designed to evaluate the safety, effectiveness, and immune response of an investigational mRNA-based acne vaccine in adults aged 18 to 45 with moderate to severe acne.

The investigational vaccine targets specific proteins in C. acnes that contribute to inflammation and acne development.

Who Can Participate?

• Aged 18–45
• Moderate to severe facial acne
• Willing to undergo a washout of acne treatments
• No prior use of oral isotretinoin (Accutane)
• Using contraception or post-menopausal (if female)
• No other facial skin conditions affecting assessments

What to Expect

If eligible, participants will be on study for 8 months, with optional long-term follow-up up to 3 years. There will be 13 clinic visits, including physical exams, vital signs, ECGs, blood tests, pregnancy tests, and vaccinations.

Participants will receive 2 vaccinations using different dose combinations of the investigational vaccine or placebo. This is a blinded study, meaning participants will not know which group they are assigned to.

Reimbursement is available for eligible participants.